Lifecore Biomedical (Lifecore Biomedical) Change In Working Capital : $20.0 Mil (TTM As of May. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Change In Working Capital?

Lifecore Biomedical's change in working capital for the quarter that ended in May. 2023 was $5.8 Mil.

Lifecore Biomedical's change in working capital for the fiscal year that ended in May. 2023 was $20.0 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Lifecore Biomedical Change In Working Capital Historical Data

The historical data trend for Lifecore Biomedical's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Change In Working Capital Chart

Lifecore Biomedical Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

Change In Working Capital

Get a 7-Day Free Trial

-1.60

-27.38

9.76

-3.10

20.03

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
Change In Working Capital	Get a 7-Day Free Trial															5.71	6.82	4.08	3.34	5.78

Lifecore Biomedical Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in May. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Lifecore Biomedical Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website

https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.

Executives

Raymond T. White	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper	director	12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian	director	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter	director	C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg	officer: Chief Financial Officer	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles	director	CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall	officer: Executive Vice President	3515 LYMAN BLVD., CHASKA MN 55318